Calidi Biotherapeutics (NYSEAMERICAN:CLDI) Issues Earnings Results

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) announced its earnings results on Thursday. The company reported ($2.94) earnings per share for the quarter, FiscalAI reports.

Calidi Biotherapeutics Stock Performance

NYSEAMERICAN:CLDI traded up $0.05 during midday trading on Friday, reaching $1.59. The stock had a trading volume of 153,482 shares, compared to its average volume of 486,976. The firm has a fifty day simple moving average of $2.13 and a two-hundred day simple moving average of $5.23. Calidi Biotherapeutics has a 12-month low of $1.48 and a 12-month high of $86.18. The company has a quick ratio of 1.92, a current ratio of 1.92 and a debt-to-equity ratio of 0.15. The stock has a market cap of $1.92 million, a P/E ratio of -0.03 and a beta of 1.33.

Hedge Funds Weigh In On Calidi Biotherapeutics

Large investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new stake in shares of Calidi Biotherapeutics in the 4th quarter worth $25,000. Geode Capital Management LLC boosted its holdings in shares of Calidi Biotherapeutics by 41.7% in the fourth quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock valued at $49,000 after acquiring an additional 12,334 shares in the last quarter. Finally, DRW Securities LLC acquired a new position in shares of Calidi Biotherapeutics during the fourth quarter worth about $173,000. Hedge funds and other institutional investors own 12.53% of the company’s stock.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.